预约演示
更新于：2026-01-27
Dexketoprofen Trometamol
右酮洛芬氨丁三醇
更新于：2026-01-27
概要
基本信息
原研机构 |
在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-NSHDSACASA-N |
CAS号22161-81-5 |
关联
88
项与 右酮洛芬氨丁三醇 相关的临床试验CTR20250538
一项多中心、随机、双盲、安慰剂平行对照设计，评价右酮洛芬氨丁三醇注射液治疗术后中至重度疼痛的安全性和有效性研究
NCT06878014
Comparison of Safety Profile and Efficacy of Different Doses of Intrathecal Morphine in Total Hip Replacement.
ChiCTR2500113664
Clinical application of dexketoprofen trometamol injection in patients undergoing hysteroscopic surgery without opioid anesthesia: A prospective, randomized, controlled trial
100 项与 右酮洛芬氨丁三醇 相关的临床结果
登录后查看更多信息
100 项与 右酮洛芬氨丁三醇 相关的转化医学
登录后查看更多信息
100 项与 右酮洛芬氨丁三醇 相关的专利（医药）
登录后查看更多信息
1,071
项与 右酮洛芬氨丁三醇 相关的文献（医药）2026-02-01ANNALS OF EMERGENCY MEDICINE
Analgesic and Anxiolytic Effects of Virtual Reality and Classical Music Therapy on Tension-Type Headache: A Randomized Controlled Trial
Article
作者: Dönmez, Safa ; Şener, Alp ; Işık, Nurullah İshak ; Akbaş, İlker ; Koca, Senem
STUDY OBJECTIVE:
Tension-type headache is the most common primary headache worldwide, significantly reducing individuals' quality of life. Although nonsteroidal anti-inflammatory drugs are commonly used for the pharmacologic treatment of tension-type headache, complementary and alternative treatment methods are gaining increasing importance. In this context, virtual reality technology stands out as a noninvasive option, particularly in pain management. This study investigates the analgesic effects and acute mood changes associated with virtual reality and classical music therapy in tension-type headache patients.
METHODS:
This randomized controlled trial involved 140 patients diagnosed with tension-type headache, divided into 2 groups. The control group received intravenous 25-mg dexketoprofen trometamol, whereas the intervention group was provided with virtual reality goggles to listen to classical music in a simulated forest environment in addition to this treatment. Pain intensity was assessed using the visual analog scale (VAS), whereas mood changes were measured using a 5-choice ordinal rating scale.
RESULTS:
The mean (SD) values for VAS-0, VAS-30, VAS-60, and VAS-120 in the control group were found to be 80.5 (11.2), 60.1 (17.0), 51.0 (18.0), and 45.9 (19.9), respectively, whereas the mean (SD) values for VAS-0, VAS-30, VAS-60, and VAS-120 in the intervention group were calculated as 79.8 (11.3), 40.35 (26.6), 21.9 (22.2), and 12.1 (15.7), respectively. Pain intensity was observed lower in the intervention group throughout the treatment than the control group. When ΔVAS-30, ΔVAS-60, and ΔVAS-120 values were examined, the values in the control group were 20.3 (13.4), 29.4 (15.9), and 34.5 (17.9), respectively, whereas in the intervention group, these values were 39.5 (22.5), 57.9 (20.1), and 67.7 (15.5), respectively. Regarding the ΔVAS%-30, ΔVAS%-60, and ΔVAS%-120 values, the control group had values of 25.5 (16.2), 36.8 (19.4), and 43.2 (21.9), respectively, whereas the intervention group had values of 50.9 (30.5), 73.6 (25.7), and 85.4 (18.4), respectively. At 120 minutes, the proportion of patients reporting a 5-choice ordinal rating scale score of 4 or 5 (indicating a positive mood) was significantly higher in the intervention group: 81.4% versus 31.4%, with a difference of 50% (95% confidence interval 35.8% to 64.2%).
CONCLUSION:
The findings suggest that the combination of virtual reality and classical music effectively manages pain and improves mood in tension-type headache patients. This approach may reduce medication use and offers an innovative alternative for tension-type headache management, consistent with similar studies in the literature.
2026-02-01Clinical and Experimental Dental Research
Dexketoprofen Time‐Dependent Administration After Third Molar Extraction: A Pilot Randomized Cross‐Over Controlled Trial
Article
作者: Tamimi, Faleh ; Sáez‐Alcaide, Luis Miguel ; Ruiz, Leire Virto ; Al‐Waeli, Haider ; Abusamak, Mohammad ; García‐Denche, Jesus Torres ; Pérez‐González, Fabián
ABSTRACT:
Objective:
To assess how chronotherapy influences recovery after bilateral third molar extraction when Dexketoprofen is administered as an anti‐inflammatory agent.
Material and Methods:
A randomized cross‐over controlled trial with 10 patients with bilateral impacted third molar extraction was enrolled. For 7 days after the surgery, the chronotherapy group was prescribed one dose of Dexketoprofen (25 mg) limited to daytime, while the control group were given two doses per day (every 12 h). Pain intensity was recorded at baseline, 24, 48, and 72 h, while facial swelling parameters were evaluated at baseline, 24, 72, and 168 h (Day 7) postoperatively. Also, the inflammatory profile was analyzed for each patient by blood samples at baseline, 72 and 168 h. The concentrations of IL‐1β, IL‐1a, IL‐2, IL‐4, IL‐6, IL‐7, IL‐10, and IL‐13 were measured using high‐sensitivity multiplex map human immunoassays.
Results:
No significant differences in postoperative VAS pain, swelling, and mouth opening (trismus) measures were observed between the two groups. However, the chronotherapy group had reduced overall postoperative complications compared to the control group. Regarding postoperative recovery, pain intensity scores in the chronotherapy group at 24, 48, and 72 h indicated a faster recovery than the control group. Blood samples analysis showed no statistical differences between the different inflammatory markers studied at 72 h or Day 7 in both groups.
Conclusions:
Daytime administration of NSAIDs might be sufficient to manage postoperative pain after third molar extraction, and complications were similar between both groups.Clinical Trial Registration:
clinicaltrials. gov, Identifier database: NCT05176158.
2026-02-01Pain and Therapy
The Role of Dexketoprofen/Tramadol in Multimodal Therapy to Prevent Acute Postsurgical and Acute Low Back Pain from Developing into Chronic Pain: A Delphi Consensus Study
Article
INTRODUCTION:
Dexketoprofen/tramadol is a fixed-dose multimodal combination analgesic that significantly controls multiple acute pain states, and may have an important clinical application in providing pain control adequate to prevent the transition from acute to chronic postsurgical and low back pain. A consensus is needed to quantify and define the actual burden of postsurgical pain (PSP) and low back pain (LBP), which can support efforts toward effective approaches to manage potential pain chronification.
METHODS:
This study utilized a modified Delphi approach. A Scientific Committee set forth 28 statements on six themes about the burden of acute PSP and LBP, their potential transition to chronic pain, their pathophysiology, therapeutic approaches to stop this transition, and the role of multimodal analgesia in this context, specifically a fixed-dose combination oral product of dexketoprofen/tramadol. An international panel of healthcare professionals from various regions and relevant medical specialties participated in a Delphi study and were surveyed for consensus on a 5-point Likert scale with consensus defined as > 70% concordance. A round of online voting lasting 3 months and using an online survey platform was permitted for each participant.
RESULTS:
A total of 100 experts completed the Delphi survey. All the 28 proposed statements reached consensus > 70% in the first round of voting. A fixed-dose combination product, specifically dexketoprofen/tramadol was recognized as a multimodal analgesic which could effectively relieve acute pain and act to prevent its transition to chronic pain. The high global burden of chronic PSP (CPSP) and chronic LBP (CLBP) was identified as well.
CONCLUSIONS:
Healthcare professionals who deal with pain recognize the burden of acute pain, the risks of acute pain transitioning to chronic pain, and inspire to avert the transition by providing effective multimodal control of acute pain. The role of fixed-dose combination analgesics, in particular dexketoprofen/tramadol, was recognized by consensus as an efficacious and safe therapy option for these acute pain syndromes. A Video Abstract is available for this article. To view, please see the online version of the manuscript or follow the 'Digital Features' link. A Video Abstract for The Role of Dexketoprofen/Tramadol in Multimodal Therapy to Prevent Acute Postsurgical and Acute Low Back Pain from Developing into Chronic Pain: A Delphi Consensus Study (MP4 112565 KB).
100 项与 右酮洛芬氨丁三醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 中国 | 2023-05-29 | |
| 偏头痛 | 中国 | 2006-10-27 | |
| 疼痛 | 中国 | 2006-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性疼痛 | 临床3期 | 中国 | 2023-11-02 | |
| 绞痛 | 临床3期 | 中国 | 2018-12-27 | |
| 腰痛 | 临床3期 | 中国 | 2018-12-27 | |
| 镇痛 | 临床3期 | 中国 | 2015-10-16 | |
| 中度疼痛 | 临床3期 | 中国 | 2015-10-16 | |
| 重度疼痛 | 临床3期 | 中国 | 2015-10-16 | |
| 背痛 | 临床3期 | 中国 | 2015-07-15 | |
| 肾绞痛 | 临床3期 | 中国 | 2015-07-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | Dexketoprofen chronotherapy | 鹹獵餘獵鏇鏇築淵構選(鏇膚鑰積鏇選鏇壓鏇範) = 鹹構鑰遞壓範夢繭遞構 廠簾齋鹹觸鹽繭憲夢糧 (遞鏇夢築願醖範衊選鬱 ) 更多 | 积极 | 2026-02-01 | ||
Dexketoprofen control therapy | 鹹獵餘獵鏇鏇築淵構選(鏇膚鑰積鏇選鏇壓鏇範) = 夢遞鹹鏇蓋顧選夢糧積 廠簾齋鹹觸鹽繭憲夢糧 (遞鏇夢築願醖範衊選鬱 ) 更多 | ||||||
临床3期 | - | - | Dexketoprofen 25 mg/Vitamin B (Thiamine 100 mg, Pyridoxine 50 mg, Cyanocobalamin 0.50 mg) FDC | 簾網膚襯窪選繭製衊糧(築餘遞襯繭製醖餘淵範) = 獵鹽製餘夢壓壓齋膚構 願鏇壓獵鹽鹹淵鹹糧構 (繭夢膚糧獵簾鹽蓋壓廠, 2.5 ~ 10.5) | 积极 | 2024-06-01 | |
簾網膚襯窪選繭製衊糧(築餘遞襯繭製醖餘淵範) = 願襯顧製簾醖糧獵夢夢 願鏇壓獵鹽鹹淵鹹糧構 (繭夢膚糧獵簾鹽蓋壓廠, 5.0 ~ 13.8) | |||||||
临床3期 | 641 | 顧築簾觸廠簾鑰餘範獵(範醖糧壓膚襯襯膚簾願): P-Value = 0.019 | 积极 | 2016-02-01 | |||
临床4期 | 224 | (Dexketoprofen) | 窪鏇鏇淵繭遞顧選網網(窪糧窪艱選願積淵蓋鹽) = 網憲廠餘蓋鹽遞鹹鬱襯 鏇蓋壓鑰觸獵鹽遞鹽餘 (糧顧積廠餘衊願夢夢範, 醖衊築衊選淵餘鹽簾鹽 ~ 蓋鑰簾蓋壓齋積蓋膚鏇) 更多 | - | 2015-07-23 | ||
(Normal Slaline) | 窪鏇鏇淵繭遞顧選網網(窪糧窪艱選願積淵蓋鹽) = 壓繭夢襯鏇鹽築艱鹽廠 鏇蓋壓鑰觸獵鹽遞鹽餘 (糧顧積廠餘衊願夢夢範, 夢廠鹹膚獵簾鹽鬱廠齋 ~ 襯觸襯夢齋鏇觸觸積網) 更多 | ||||||
临床1期 | 26 | (Enantyum® Oral Solution) | 鏇選憲夢糧鹹願醖築夢(壓壓夢鹽繭網鏇製艱築) = 淵醖築醖窪艱壓鏇齋廠 鏇襯衊積簾壓蓋壓夢餘 (積壓選廠蓋憲獵艱衊獵, 顧衊繭顧築獵艱築蓋襯 ~ 繭鏇淵憲醖製網憲衊築) 更多 | - | 2015-07-09 | ||
(Keral® Tablet) | 鏇選憲夢糧鹹願醖築夢(壓壓夢鹽繭網鏇製艱築) = 艱簾築醖鏇艱積窪選觸 鏇襯衊積簾壓蓋壓夢餘 (積壓選廠蓋憲獵艱衊獵, 繭襯淵鑰憲製繭範鏇淵 ~ 鑰淵鹹廠鏇蓋壓糧衊齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用